Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)
Completed
Cephalon
Phase 3
2004-02-01
The primary objective of this study is to determine whether treatment with Armodafinil
(CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness
associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep
latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps
at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings
(as related to general condition) at week 12, or last post-baseline visit.
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Completed
Cephalon
Phase 4
2006-08-01
This is a six week, double blind,placebo controlled study for patients with schizophrenia or
schizoaffective disorder treated with an atypical antipsychotic for at least two months.
Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current
antipsychotic and tested at baseline and week 6 for differences in memory, attention and
problem-solving ability. Changes in weight during the six week study will also be tracked.
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Completed
National Alliance for Research on Schizophrenia and Depression
Phase 4
2006-08-01
This is a six week, double blind,placebo controlled study for patients with schizophrenia or
schizoaffective disorder treated with an atypical antipsychotic for at least two months.
Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current
antipsychotic and tested at baseline and week 6 for differences in memory, attention and
problem-solving ability. Changes in weight during the six week study will also be tracked.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.